|Articles|September 16, 2022
NeurologyLive® Friday 5 — September 16, 2022
Author(s)NeurologyLive® Staff
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 16, 2022.
Advertisement
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Peer Exchange: Unmet Needs in Multiple Sclerosis Clinical Trial Design
Ahmed Obeidat, MD, PhD; Benjamin Greenberg, MD; and Hesham Abboud, MD, comment on the need for more inclusive clinical trial patient enrollment criteria, highlighting underserved patient populations in episode 2 of the NeurologyLive® Peer Exchange series, "Multiple Sclerosis Treatments on the Horizon: BTK Inhibitors."
2: International Parkinson and Movement Disorders Society Congress
Following along with NeurologyLive®'s coverage of the International Parkinson and Movement Disorder Society (MDS) Annual Meeting, which gathers thousands of clinicians, researchers, trainees, and industry supporters to discuss the diagnosis and treatment of movement disorders on an annual basis.
3: NeuroVoices: Lynn Bekris, PhD, on Future Research for sTREM2, GFAP, and Immunotherapies in Alzheimer Disease
In the latest edition of our in-depth Q&A series, the molecular biologist at the Cleveland Clinic Lerner Research Institute discussed the unanswered questions regarding biomarkers sTREM2 and GFAP, and the role they play in Alzheimer pathology.
4: NurOwn Treatment Shows Positive Results in Phase 2 Study of Progressive Multiple Sclerosis
Treatment with NurOwn resulted in response on several secondary outcomes, including timed 25-foot walk, 12-item multiple sclerosis walking scale, and low contrast letter acuity, among others.
5: Transitioning Sleep Schedules for School in Pediatric Patients: Carol Rosen, MD
The professor of pediatrics at Case Western University discussed the complexities and negative effects for children drastically change their sleep schedules as school begins.
—————————————————
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
September 15th 2025
- 2025 Women in Neurology Conference: Educating, Mentoring, and Networking
September 15th 2025
- This Week on NeurologyLive® — September 15, 2025
September 15th 2025
- NeurologyLive® Brain Games: September 14, 2025
September 14th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
3
10 Years of the Women Neurologists Group: A Preview of the 4th Annual Conference
4
This Week on NeurologyLive® — September 15, 2025
5